Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 4, July-August, p. 643–648

doi: 10.17219/acem/41191

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Comparable Function of γ-Tocopherols in Asthma Remission by Affecting Eotaxin and IL-4

Yan-Mei Wu1,A, Zhi-Wen Xue1,B, Li-Li Zhang1,C, Ning-Mei Gao1,C, Xiao-Mei Du1,D, Xiao-Yan Zhang1,D, Zhuo-Hong Zhang1,C, Zhi-Guo Zhang1,B

1 Department of Respiratory and Blood Oncology, Xi’An XD Group Hospital, ShaanXi, Xi’an, China

Abstract

Background. Bronchial asthma is one of the world’s most common chronic disorders dangerous to human health. It has been hypothesized that the increased number of asthma sufferers may be due to changing antioxidant intake or vitamin deficiency. However, the influence of vitamins on asthma has rarely been considered.
Objectives. The aim of this study was to explore the effects of γ-tocopherols, a specific form of vitamin E, on asthma remission together with the possible mechanism behind the process.
Material and Methods. Eosinophil counting was applied to detect the total number of cells, eosinophils and lymphocytes. Meanwhile, HE staining was used for morphological detection. In addition, the eotaxin and IL-4 levels in the serum and bronchoalveolar lavage fluid were measured using ELISA technology.
Results. The cell counting results showed that γ-tocopherols possesses the capability to reduce the number of eosinophils. Moreover, the exudation of inflammatory cells together with the hyperplasia of goblet cells was also found to experience significant inhibition when treated with γ-tocopherols. Furthermore, the high levels of eotaxin and IL-4 in the asthma group were evidently reduced under the treatment of γ-tocopherols which was comparable with hexadecadrol.
Conclusion. γ-tocopherols can remit asthma by regulating the level of eotaxin and IL-4. Moreover, γ-tocopherols may be regarded as a potential candidate for asthma treatment after much deeper explorations.

Key words

asthma, γ-tocopherols, dexamethasone, eotaxin, IL-4

References (28)

  1. Burioka N: Chronotherapy of bronchial asthma. Nihon Rinsho 2013, 71, 2146–2152.
  2. Allan K, Devereux G: Diet and asthma: Nutrition implications from prevention to treatment. J Am Diet Assoc 2011, 111, 258–268.
  3. Dworski R, Han W, Blackwell TS, Hoskins A, Freeman ML: Vitamin E prevents NRF2 suppression by allergens in asthmatic alveolar macrophages in vivo. Free Radic Biol Med 2011, 51, 516–521.
  4. Han YY, Blatter J, Brehm JM, Forno E, Litonjua AA, Celedon JC: Diet and asthma: Vitamins and methyl donors. Lancet Respir Med 2013, 1, 813–822.
  5. Mabalirajan U, Aich J, Leishangthem GD, Sharma SK, Dinda AK, Ghosh B: Effects of vitamin E on mitochondrial dysfunction and asthma features in an experimental allergic murine model. J Appl Physiol 2009, 107, 1285–1292.
  6. Ghaffari J, Farid Hossiani R, Khalilian A, Nahanmoghadam N, Salehifar E, Rafatpanah H: Vitamin e supplementation, lung functions and clinical manifestations in children with moderate asthma: A randomized double blind placebo-controlled trial. Iran J Allergy Asthma Immunol 2014, 13, 98–103.
  7. Liang W, Zhou Z, Ji Z, Wang Y, Xue W, Zhang X: Association study of bronchial asthma with polymorphisms of IL-4 and IL-4R receptor genes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2014, 31, 97–100.
  8. Hernandez ML, Wagner JG, Kala A, Mills K, Wells HB, Alexis NE, Lay JC, Jiang Q, Zhang H, Zhou H, Peden DB: Vitamin E, gamma-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers. Free Radic Biol Med 2013, 60, 56–62.
  9. Jiang Q: Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med 2014, 72, 76–90.
  10. Jian YR, Chang SY, Lin PY, Yang YH, Chuang YH: Inactivated influenza virus vaccine is efficient and reduces IL-4 and IL-6 in allergic asthma mice. Influenza Other Respir Viruses 2013, 7, 1210–1217.
  11. Kim CK, Callaway Z, Kim DW, Kita H: Eosinophil degranulation is more important than eosinophilia in identifying asthma in chronic cough. J Asthma 2011, 48, 994–1000.
  12. Paplinska M, Hermanowicz-Salamon J, Nejman-Gryz P, Bialek-Gosk K, Rubinsztajn R, Arcimowicz M, Placha G, Gora J, Chazan R, Grubek-Jaworska H: Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients. Cytokine 2012, 60, 393–399.
  13. Wang ZD, Lian D, Shen JL, Sun R, Xu W, Xin Z, Lei L, Jin LH, Jin SD: Association between the interleukin-4, interleukin-13 polymorphisms and asthma: A meta-analysis. Mol Biol Rep 2013, 40, 1365–1376.
  14. Zimmermann N, Hogan SP, Mishra A, Brandt EB, Bodette TR, Pope SM, Finkelman FD, Rothenberg ME: Murine eotaxin-2: A constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression. J Immunol 2000, 165, 5839–5846.
  15. Moore PE, Church TL, Chism DD, Panettieri RA, Shore SA: IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: A role for ERK 2002, 282, 847–853.
  16. De Vooght V, Smulders S, Haenen S, Belmans J, Opdenakker G, Verbeken E, Nemery B, Hoet PH, Vanoirbeek JA: Neutrophil and eosinophil granulocytes as key players in a mouse model of chemical-induced asthma. Toxicol Sci 2013, 131, 406–418.
  17. Muniz-Junqueira MI, Barbosa-Marques SM, Junqueira LF Jr: Morphological changes in eosinophils are reliable markers of the severity of an acute asthma exacerbation in children. Allergy 2013, 68, 911–920.
  18. Tamaoki J: Bronchial asthma: Progress in diagnosis and treatments. Topics: IV. Subtype/particular type/comorbidities; 2. Allergic rhinitis and obesity. Nihon Naika Gakkai Zasshi 2013, 102, 1412–1418.
  19. Sahiner UM, Birben E, Erzurum S, Sackesen C, Kalayci O: Oxidative stress in asthma. World Allergy Organ J 2011, 4, 151–158.
  20. Kirkham P, Rahman I: Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol Ther 2006, 111, 476–494.
  21. Wood LG, Garg ML, Blake RJ, Simpson JL, Gibson PG: Oxidized vitamin E and glutathione as markers of clinical status in asthma. Clin Nutr 2008, 27, 579–586.
  22. Beal DR, Stepien DM, Natarajan S, Kim J, Remick DG: Reduction of eotaxin production and eosinophil recruitment by pulmonary autologous macrophage transfer in a cockroach allergen-induced asthma model. Am J Physiol Lung Cell Mol Physiol 2013, 305, 866–877.
  23. Gong J, Ren D, Luo Y, Lai W, Li J, Wang W: Effects of dexamethasone on expressions of IL-21 and its receptor in lungs of experimental asthma mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013, 29, 561–564.
  24. Keeney GE, Gray MP, Morrison AK, Levas MN, Kessler EA, Hill GD, Gorelick MH, Jackson JL: Dexamethasone for acute asthma exacerbations in children: A meta-analysis. Pediatrics 2014, 133, 493–499.
  25. Meyer JS, Riese J, Biondi E: Is dexamethasone an effective alternative to oral prednisone in the treatment of pediatric asthma exacerbations? Hosp Pediatr 2014, 4, 172–180.
  26. Shimamura T, Husain SR, Puri RK: The IL-4 and IL-13 pseudomonas exotoxins: New hope for brain tumor therapy. Neurosurg Focus 2006, 20, E11.
  27. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK: Safety, tolerability, and tumor response of IL4-pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64, 125–137.
  28. Rainov NG, Heidecke V: Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J Neurooncol 2004, 66, 197–201.